Ark Biosciences

Ark Biosciences is a biopharmaceutical company based in Shanghai, dedicated to discovering and developing innovative drugs for unmet medical needs.

The company focuses on areas such as respiratory, infectious, and pediatric diseases. Its pipeline features ziresovir, the first direct-acting RSV antiviral drug developed by Ark Biosciences, and AK0705, a drug candidate aimed at treating COPD. The company specializes in drug discovery, preclinical and clinical development, and R&D collaboration. Ark Biosciences has established strategic partnerships with pharmaceutical companies and academic institutions, including a cooperation agreement with WuXi AppTec to support integrated new-drug research and development. While specific commercialized products are not highlighted, the company emphasizes its drug candidates and collaborative efforts in advancing healthcare solutions.